SLP · Nasdaq · ·
$18.480.0%Sep 29 close
The quarter ending May 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMay 31, 2026 | 3 months toMay 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $21.9M | $20.4M | +7.48% |
| Profit | $3.6M | -$67.3M | +105.31% |
| Profit per share | $0.18 | -$3.35 | +105.37% |
| Free Cash Flow | $8.6M | $7.8M | +9.80% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Simulations Plus, Inc. has no earnings call transcript available.
“We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software revenue was flat year over year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Simulations Plus, Inc.’s Item 2.02 8-K filed July 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.